Literature DB >> 24693984

The Clostridium difficile proline racemase is not essential for early logarithmic growth and infection.

Xiaoqian Wu1, Julian G Hurdle.   

Abstract

Proline racemase (PrdF), which is important for energy metabolism via the Stickland pathway and is unique to certain clostridia, was investigated as a potential anti-Clostridium difficile target by examining its effects on the growth and virulence of C. difficile. Inactivation of PrdF by insertional mutagenesis did not affect early logarithmic growth but only attenuated growth in the mid- and late logarithmic phases. There was no effect on virulence in vivo, suggesting that PrdF is also not required for C. difficile infection. These findings indicate that PrdF as well as other enzymes encoded by the proline reductase operon are all nonessential and are unsuitable targets for anti-C. difficile drug discovery.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24693984      PMCID: PMC4076780          DOI: 10.1139/cjm-2013-0903

Source DB:  PubMed          Journal:  Can J Microbiol        ISSN: 0008-4166            Impact factor:   2.419


  15 in total

1.  Studies in the metabolism of the strict anaerobes (genus Clostridium): The oxidation of alanine by Cl. sporogenes. IV. The reduction of glycine by Cl. sporogenes.

Authors:  L H Stickland
Journal:  Biochem J       Date:  1935-04       Impact factor: 3.857

2.  A modular system for Clostridium shuttle plasmids.

Authors:  John T Heap; Oliver J Pennington; Stephen T Cartman; Nigel P Minton
Journal:  J Microbiol Methods       Date:  2009-05-13       Impact factor: 2.363

3.  Analysis of proline reduction in the nosocomial pathogen Clostridium difficile.

Authors:  Sarah Jackson; Mary Calos; Andrew Myers; William T Self
Journal:  J Bacteriol       Date:  2006-10-13       Impact factor: 3.490

Review 4.  Targeting bacterial membrane function: an underexploited mechanism for treating persistent infections.

Authors:  Julian G Hurdle; Alex J O'Neill; Ian Chopra; Richard E Lee
Journal:  Nat Rev Microbiol       Date:  2011-01       Impact factor: 60.633

5.  Identification of a human trans-3-hydroxy-L-proline dehydratase, the first characterized member of a novel family of proline racemase-like enzymes.

Authors:  Wouter F Visser; Nanda M Verhoeven-Duif; Tom J de Koning
Journal:  J Biol Chem       Date:  2012-04-23       Impact factor: 5.157

6.  A defined growth medium for Clostridium difficile.

Authors:  T Karasawa; S Ikoma; K Yamakawa; S Nakamura
Journal:  Microbiology       Date:  1995-02       Impact factor: 2.777

7.  The ClosTron: Mutagenesis in Clostridium refined and streamlined.

Authors:  John T Heap; Sarah A Kuehne; Muhammad Ehsaan; Stephen T Cartman; Clare M Cooksley; Jamie C Scott; Nigel P Minton
Journal:  J Microbiol Methods       Date:  2009-11-03       Impact factor: 2.363

8.  The membrane as a target for controlling hypervirulent Clostridium difficile infections.

Authors:  Xiaoqian Wu; Philip T Cherian; Richard E Lee; Julian G Hurdle
Journal:  J Antimicrob Chemother       Date:  2012-12-21       Impact factor: 5.790

9.  The physiology of Clostridium sporogenes NCIB 8053 growing in defined media.

Authors:  R W Lovitt; D B Kell; J G Morris
Journal:  J Appl Bacteriol       Date:  1987-01

Review 10.  Clostridium difficile infection: new developments in epidemiology and pathogenesis.

Authors:  Maja Rupnik; Mark H Wilcox; Dale N Gerding
Journal:  Nat Rev Microbiol       Date:  2009-07       Impact factor: 60.633

View more
  9 in total

1.  The Clostridium difficile Dlt Pathway Is Controlled by the Extracytoplasmic Function Sigma Factor σV in Response to Lysozyme.

Authors:  Emily C Woods; Kathryn L Nawrocki; Jose M Suárez; Shonna M McBride
Journal:  Infect Immun       Date:  2016-05-24       Impact factor: 3.441

Review 2.  Role of Proline in Pathogen and Host Interactions.

Authors:  Shelbi L Christgen; Donald F Becker
Journal:  Antioxid Redox Signal       Date:  2018-02-02       Impact factor: 8.401

3.  Rifamycin Resistance in Clostridium difficile Is Generally Associated with a Low Fitness Burden.

Authors:  Uyen T Dang; Idalia Zamora; Kirk E Hevener; Sudip Adhikari; Xiaoqian Wu; Julian G Hurdle
Journal:  Antimicrob Agents Chemother       Date:  2016-08-22       Impact factor: 5.191

4.  A curated C. difficile strain 630 metabolic network: prediction of essential targets and inhibitors.

Authors:  Mathieu Larocque; Thierry Chénard; Rafael Najmanovich
Journal:  BMC Syst Biol       Date:  2014-10-15

5.  The Immune Protein Calprotectin Impacts Clostridioides difficile Metabolism through Zinc Limitation.

Authors:  Christopher A Lopez; William N Beavers; Andy Weiss; Reece J Knippel; Joseph P Zackular; Walter Chazin; Eric P Skaar
Journal:  mBio       Date:  2019-11-19       Impact factor: 7.867

6.  The Fatty Acid Synthesis Protein Enoyl-ACP Reductase II (FabK) is a Target for Narrow-Spectrum Antibacterials for Clostridium difficile Infection.

Authors:  Ravi K R Marreddy; Xiaoqian Wu; Madhab Sapkota; Allan M Prior; Jesse A Jones; Dianqing Sun; Kirk E Hevener; Julian G Hurdle
Journal:  ACS Infect Dis       Date:  2018-12-13       Impact factor: 5.084

7.  Molecular and Mechanistic Characterization of PddB, the First PLP-Independent 2,4-Diaminobutyric Acid Racemase Discovered in an Actinobacterial D-Amino Acid Homopolymer Biosynthesis.

Authors:  Kazuya Yamanaka; Ryo Ozaki; Yoshimitsu Hamano; Tadao Oikawa
Journal:  Front Microbiol       Date:  2021-06-10       Impact factor: 5.640

8.  Importance of Glutamate Dehydrogenase (GDH) in Clostridium difficile Colonization In Vivo.

Authors:  Brintha Parasumanna Girinathan; Sterling Braun; Apoorva Reddy Sirigireddy; Jose Espinola Lopez; Revathi Govind
Journal:  PLoS One       Date:  2016-07-28       Impact factor: 3.240

9.  Novel Drivers of Virulence in Clostridioides difficile Identified via Context-Specific Metabolic Network Analysis.

Authors:  Matthew L Jenior; Jhansi L Leslie; Deborah A Powers; Elizabeth M Garrett; Kimberly A Walker; Mary E Dickenson; William A Petri; Rita Tamayo; Jason A Papin
Journal:  mSystems       Date:  2021-10-05       Impact factor: 7.324

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.